Viatris stock slides 24% as analysts say sale of biosimilars to Indian partner removes key growth driver

Viatris Inc. said Monday it has agreed to combine its biosimilars portfolio with privately held Indian company Biocon Biologics Ltd. for up to $3.335 billion, as part of a broader overhaul of its business following a strategic review.